- Aminlou, M., & Yaghoubi, Y. (2019). The policies of intellectual property system for innovation development [In Persian].
Journal of Science & Technology Policy,
11(2), 269-284.
http://jstp.nrisp.ac.ir/article_13698.html
- Bakhtiari, M.R. (2011). Principles of intellectual property and patent protection [In Persian]. Iranian Research Organization for Science and Technology.
- Cockburn, I. M. (2009). Intellectual property rights and pharmaceuticals: challenges and opportunities for economic research. In
The economics of intellectual property:
Suggestions for further research in developing countries and countries with economies in transition (pp. 150-180). World Intellectual Property Organization.
https://www.wipo.int/ip-development/en/economics/pdf/wo_1012_e.pdf
- De Leon, I., Donoso, J. F., & de León, I. (2017).
Innovation, startups and intellectual property management: Strategies and evidence from Latin America and other regions. Springer.
https://doi.org/10.1007/978-3-319-54906-4
- Dijkman, L.(2020
).Reflections on IP exclusivity in the wake of the Corona virus outbreak, Retrived from
http://ipkitten.blogspot.com/2020/03/reflections-on-ip-exclusivity-in-wake.html
- Fisher III, W. W., & Oberholzer-Gee, F. (2013). Strategic management of intellectual property: An integrated approach.
California Management Review,
55(4), 157-183.
https://doi.org/10.1525/cmr.2013.55.4.157
- Frazier, K. C. (2015).
Biopharmaceutical research & development: The process behind new medicines. http://phrma-docs.phrma.org/sites/default/files/pdf/rd_brochure_022307.pdf
- Gargate, G., & Momaya, K. (2018).
Intellectual property management system: Develop and self-assess. World Patent Information,
52, 29–41.
https://doi.org/10.1016/j.wpi.2018.01.005.
- Goodarzi, M. & Esmaeeli, E. (2013). Management of intellectual property in Iranian state research institutes: A few Items study [In Persian].
Rahyaft,
23(2), 33-51.
http://rahyaft.nrisp.ac.ir/article_13544.html
- Goodarzi, M. (2003). Investigating the status-quo of Iran's intellectual property system and providing solutions for improvement toward development [Unpublished master's thesis, Allameh Tabatabaei University, Tehran, Iran, In Persian].
- Holgersson, M. & Aaboen, L.(2019). A literature review of intellectual property management in technology transfer offices: From appropriation to utilization.
Technology in Society, 59, 101132.
https://doi.org/10.1016/j.techsoc.2019.04.008
- Islamic Parliament of Iran. (2007).
Patent, Industrial Designs and Trademarks Law [In Persian].
http://iripo.ssaa.ir/index.jsp?fkeyid=&siteid=4&pageid=373&p=1&g=37&showitem=8
- Jolly, A., & Philpott, J. (2009). The handbook of European intellectual property management: Developing, managing and protecting your company's intellectual property. Kogan Page.
- Lawshe, CH. (1975) A qualitative approach to content validity.
Personnel Psychology,
28(4), 563-75.
https://doi.org/10.1111/j.1744-6570.1975.tb01393.x
- Lewis-Lettington, R., & Grace, C. (2004).
The effect of changing intellectual property on pharmaceutical industry prospects in India and China considerations for access to medicines. DFID Health Systems Resource Centre
https://assets.publishing.service.gov.uk/media/57a08cd6ed915d3cfd00164c/The-effect-of-changing-Intellectual-property-in-India-and-China.pdf
- Lexchin, J., Bero, L., Djulbegovic, B. & Clark, O. (2003). Pharmaceutical industry sponsorship and research outcome and quality: systematic review.
Bmj,
326(7400), 1167-1170.
https://doi.org/10.1136/bmj.326.7400.1167
- Liu, T. W. (2009).
An audit model for intellectual property management excellence [Doctoral dissertation, City University of Hong Kong, Hong Kong]. Retrieved from
http://lbms03.cityu.edu.hk/theses/c_ftt/engd-meem-b23750923f.pdf
- Makati Business Club (2017).
Exploitation of Intellectual Property Rights by Pharmaceutical Companies in the Philippines.
https://mbc.com.ph/wp-content/uploads/IDAR-PHARMA-RR.pdf
- McGuire, J. L., Hasskarl, H., Bode, G., Klingmann, I. & Zahn, M. (2007). Pharmaceuticals, general survey. In Ullmann’s encyclopedia of chemical technology. Wiley-VCH, Weinheim.
- Sullivan, P. H. (2000). Value driven intellectual capital: how to convert intangible corporate assets into market value. Wiley.
- Sullivan, T. (2019, March 21
). A tough road: Cost to develop one new drug is $2.6 billion; approval rate for drugs entering clinical development is less than 12%.Policy & Medicine
. https://www.policymed.com/2014/12/a-tough-road-cost-to-develop-one-new-drug-is-26-billion-approval-rate-for-drugs-entering-clinical-de.html
- Work group for the evaluation and recognition of the qualifications of knowledge-based enterprises and institutions. (2019).
Approved knowledge-based enterprises and institutions [Data set, In Persian].
https://pub.daneshbonyan.ir
